ConductScience.org, home

Paper528374

Low heart and skin toxicity of a tetrahydropyranyl derivative of adriamycin (THP-ADM) as observed by electron and light microscopy.

Dantchev D and 4 others. J Antibiot (Tokyo), 1979. Cited by 96 papers, by iCite.

Cite this record

ConductScience Library. Low heart and skin toxicity of a tetrahydropyranyl derivative of adriamycin (THP-ADM) as observed by electron and light microscopy. Papers, record 528374. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/528374

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Low heart and skin toxicity of a tetrahydropyranyl derivative of adriamycin (THP-ADM) as observed by electron and light microscopy.
PubMed
Journal
J Antibiot (Tokyo)
PubMed
Year
1979
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
96
iCite
Relative citation ratio, by iCite
3.41
iCite
Revised in PubMed
2019-07-23
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Dantchev DD
2Paintrand MM
3Hayat MM
4Bourut CC
5Mathé GG

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AlopeciaMajor topic
CardiomyopathiesMajor topic
DoxorubicinMajor topic
Animals
Cricetinae
Mesocricetus
Mice
Myocardium
Skin
Time Factors

Source PubMed

Download CSV of topics

Cited by28

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 96 citations.

PMIDTitleJournalYearIn PapersSource
40205399
Comparison of hyperthermic intravesical chemotherapy using pirarubicin and Bacillus Calmette-Guérin in the treatment of patients with high-risk non-muscle-invasive bladder carcinoma: a retrospective study.
BMC Urol2025https://conductscience.org/library/papers/40205399PubMed
39390209Improved survival among elderly patients with aggressive adult T-cell leukemia/lymphoma: Impact of mogamulizumab-containing chemotherapy.Int J Hematol2024https://conductscience.org/library/papers/39390209PubMed
37238419Pirarubicin Combination Low-Dose Chemotherapy for Early Infantile Stage MS Neuroblastoma: Case Report.Children (Basel)2023https://conductscience.org/library/papers/37238419PubMed
37205905Oral vinorelbine and continuous low doses of cyclophosphamide in pediatric rhabdomyosarcoma: a real-world study.Front Pharmacol2023https://conductscience.org/library/papers/37205905PubMed
36575000A multicenter, phase II study of full-dose THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, aggressive non-Hodgkin lymphoma.J Clin Exp Hematop2022https://conductscience.org/library/papers/36575000PubMed
34193755A multicenter, phase II study of R-THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, indolent B-cell lymphoma.J Clin Exp Hematop2021https://conductscience.org/library/papers/34193755PubMed
32907549Efficacy of combination-chemotherapy with pirarubicin, ifosfamide, and etoposide for soft tissue sarcoma: a single-institution retrospective analysis.BMC Cancer2020https://conductscience.org/library/papers/32907549PubMed
31649535Dual Inhibition of Pirarubicin-Induced AKT and ERK Activations by Phenformin Sensitively Suppresses Bladder Cancer Growth.Front Pharmacol2019https://conductscience.org/library/papers/31649535PubMed
288240573A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis.Intern Med2017https://conductscience.org/library/papers/28824057PubMed
25432694Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter?Med Oncol2015https://conductscience.org/library/papers/25432694PubMed
22580740Pirarubicin inhibits multidrug-resistant osteosarcoma cell proliferation through induction of G2/M phase cell cycle arrest.Acta Pharmacol Sin2012https://conductscience.org/library/papers/22580740PubMed
20033628Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkin's lymphoma: single center, 15-year experience.Int J Hematol2010https://conductscience.org/library/papers/20033628PubMed
20016539Long-term results of the Japanese Childhood Cancer and Leukemia Study Group studies 811, 841, 874 and 911 on childhood acute lymphoblastic leukemia.Leukemia2010https://conductscience.org/library/papers/20016539PubMed
7805181Treatment of advanced hormone-refractory prostate carcinoma with a combination of etoposide, pirarubicin and cisplatin.Cancer Chemother Pharmacol1995https://conductscience.org/library/papers/7805181PubMed
6687222Activity of 4'-0-tetrahydropyranyladriamycin hydrochloride (THP-ADM) in a human tumor cloning system.Invest New Drugs1983https://conductscience.org/library/papers/6687222PubMed
6678865Phase I clinical trial of a new anthracycline: 4'-o-tetrahydropyranyl adriamycin.Invest New Drugs1983https://conductscience.org/library/papers/6678865PubMed
4017162Pharmacokinetics and disposition of 4'-O-tetrahydropyranyladriamycin in mice by HPLC analysis.Cancer Chemother Pharmacol1985https://conductscience.org/library/papers/4017162PubMed
3667166A phase II study of (2"R)-4'-0-tetrahydropyranyladriamycin (THP) in hematological malignancies.Invest New Drugs1987https://conductscience.org/library/papers/3667166PubMed
3478154(2"-R)-4'-o-tetrahydropyranyladriamycin, a new anthracycline derivative; its effectiveness in lymphoid malignancies.Cancer Chemother Pharmacol1987https://conductscience.org/library/papers/3478154PubMed
3315282Treatment of acute leukemia and malignant lymphoma with (2"R)-4'-O-tetrahydropyranyladriamycin.Cancer Chemother Pharmacol1987https://conductscience.org/library/papers/3315282PubMed

See all 28 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/528374

GET https://conductscience.org/api/papers/v1/528374/cited_by?page=2